AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
TOKYO, Aug 1 Asia Pulse - Takeda Chemical Industries Ltd. (TSE:4502) said Tuesday that it has obtained the U.S. and European development and marketing rights to Tokyo-Mitsubishi Pharmaceuticals Inc.'s drug to treat heart failure.
Takeda will carry out development through overseas subsidiaries. Once the drug is approved, Takeda will be able to market it worldwide except for in Japan, China, Korea and Taiwan. In Europe and the U.S. alone, there are said to be some 17 million sufferers of heart failure. Takeda aims to expand its product lineup in this area by taking in Tokyo-Mitsubishi's promising drug candidates.
The MCC-135, an oral drug for the ...